By Kelly Cloonan
Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with schizophrenia.
The company said Tuesday a Phase 3 trial of Cobenfy as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale total score compared to a placebo with an atypical antipsychotic at week six.
The results missed the threshold for statistical significance for the primary endpoint, the company said.
Preliminary analyses suggest the treatment was associated with improved schizophrenia symptoms compared to the placebo treatment for certain patients.
A post-hoc subgroup analysis showed there was a notable difference in response between subjects treated with risperidone as a background therapy and those treated with other background antipsychotics.
The company said it plans to speak with regulators about potential next steps.
Shares fell 5.6% to $47.03 on Tuesday in after-hours trading. Shares have risen 1% over the last 12 months through Tuesday's close.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 22, 2025 17:00 ET (21:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。